Kelonia Therapeutics Announces Upcoming Oral Presentation of Preclinical Data with First Details of iGPS™ Technology at ASGCT Annual Meeting

Preclinical data demonstrate iGPS particles efficiently and specifically deliver CAR molecules to T cells in vivo for durable tumor clearance without need for lymphodepleting chemotherapy

Company developing iGPS technology to provide potentially safe, efficacious, manufacturable, and widely accessible “off-the-shelf” in vivo CAR T therapies; discloses multiple myeloma as lead program

Company to share additional preclinical data during oral presentation highlighting potential of iGPS particles to generate CAR T cells clinically

BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, announced today that it will share initial preclinical data on its in vivo Gene Placement System (iGPS™) technology during an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 26^th Annual Meeting, occurring May 16-20, 2023, in Los Angeles.

The preclinical data presented will demonstrate that Kelonia’s iGPS technology uniquely enables safe and efficient in vivo generation of highly efficacious CAR T cells. In a humanized mouse model of multiple myeloma treatment, when an anti-BCMA CAR transgene was delivered directly in vivo using iGPS particles, low intravenous dose levels resulted in complete initial tumor regression comparable to ex vivo-manufactured CAR T cells. However, functional CAR T cell persistence after iGPS particle treatment resulted in significantly longer tumor control compared to ex vivo-generated CAR T cells. Despite efficient in vivo CAR gene transfer to T cells, no concerning or unexpected “off-target” transduction was observed including in vital, progenitor or reproductive organs.

“CAR T cells have been transformative for patients suffering from lethal cancers. But manufacturing unique CAR T cells for every patient has limited access to this incredible medicine. The preclinical data we’ll present at ASGCT demonstrates the potential for potent, durable and safe CAR T cells generated by our iGPS in vivo delivery technology, without the requirement for preparative chemotherapy,” said Kevin Friedman, Ph.D., Founder, President, and Chief Scientific Officer, Kelonia Therapeutics. “This is the first step toward our vision of solving the central challenge of genetic medicines: democratizing and enabling access when and where patients need them. We look forward to sharing detailed data at the conference.”

Details for the oral presentation are as follows:

Abstract Title: Potent in vivo transduction by iGPS particles generates CAR T cells with durable anti-tumor activity

Presenter: Shannon Grande Contrastano, Ph.D., Senior Director, Preclinical Sciences, Kelonia Therapeutics

Session Date/Time: Wednesday, May 17, 2023: 3:45-5:30 PM PDT

Abstract number: 90

About Kelonia Therapeutics

Kelonia is pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS^™). The company’s simple and elegant cutting-edge in vivo gene delivery technology uses an advanced lentiviral vector particle harboring envelope modifications to improve in vivo gene transfer efficiency and tropism molecules to facilitate T-cell specific delivery. With an initial focus on developing transformational in vivo CAR T therapies for hematologic cancers, Kelonia is building a pipeline of genetic medicines for a range of diseases, with the bold goal of making genetic medicines accessible to every patient in need, when and where they need them. Learn more about Kelonia at www.keloniatx.com and follow us on LinkedIn and Twitter.